Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Cocrystal Pharma, Inc. | Director | Common Stock | 1.02M | $2.02M | $1.97 | Oct 9, 2024 | Direct |
PRECIGEN, INC. | Director | Common Stock | 1.15M | $2.01M | $1.74 | Mar 14, 2025 | Direct |
PRECIGEN, INC. | Director | Restricted Stock Units | 0 | $0 | $1.74 | Mar 14, 2025 | Direct |
PRECIGEN, INC. | Director | Option to Purchase Common Stock (Right to Buy) | 83.5K | Mar 13, 2025 | Direct | ||
EyePoint Pharmaceuticals, Inc. | Director | Stock Options (Right to buy) | 60K | Sep 3, 2024 | Direct | ||
EyePoint Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 40K | Jan 3, 2025 | Direct | ||
BridgeBio Pharma, Inc. | Director | Stock Option (Right to Buy) | 26K | Jun 21, 2024 | Direct | ||
Prometheus Biosciences, Inc. | Director | Common Stock | 0 | $108.42 | Jun 16, 2023 | Direct | |
Prometheus Biosciences, Inc. | Director | Stock Option (right to buy) | 0 | Jun 16, 2023 | Direct |